Many G-protein coupled receptors involved in pain and addiction are pharmacologically and biochemically well characterized, but some orphan receptors like GPR35 and GPR55, with homology to known receptors for drugs of abuse, remain poorly characterized. GPR55 is emerging as an important target in inflammatory pain, neuropathic pain, and bone development while other studies indicate that GPR55 activation is pro-carcinogenic. GPR55 does recognize certain cannabinoid ligands, so it has been suggested to be a third cannabinoid receptor. GPR35 is an important target in pain (spinal antinociception as well as inflammatory pain), heart disease, asthma, metabolic disease, inflammatory bowel disease and cancer. Each of these areas alone is medically important and each would benefit by the use of selective agonists and antagonists to further studies in their respective animal models. However, to date, no low nanomolar potency ligands have been discovered for these receptors nor is there a radioligand developed to characterize binding. The lack of such ligands is a critical barrier to progress in this field. The goal of this proposal is to leverage our recen promising high throughput, high content screening results for GPR55 agonists and GPR35 antagonists using structure based design and cheminformatics tools to develop an SAR for selected scaffolds that leads to the identification of low nanamolar ligands that retain high receptor selectivity.
We aim to discover nanomolar potency GPR55 and GPR35 ligands using a combination of structure-based design, molecular modeling, chemoinformatics, high-throughput screening and site directed mutagenesis.
Many G-protein coupled receptors involved in pain and addiction are pharmacologically and biochemically well characterized, but some orphan receptors like GPR35 and GPR55, with homology to known receptors for drugs of abuse, remain poorly characterized. Both GPR55 and GPR35 are emerging as important targets in inflammatory pain, cancer and metabolic disease, to name a few. However, the lack of potent agonists and antagonists for these receptors are a critical barrier to progress this field. The goa of this proposal is to leverage our recent promising high throughput screening results for GPR55 agonists and GPR35 antagonists to develop such ligands.
| Abdalhameed, Manahil M; Zhao, Pingwei; Hurst, Dow P et al. (2017) Structure-activity relationships of benzothiazole GPR35 antagonists. Bioorg Med Chem Lett 27:612-615 |
| Howlett, Allyn C; Abood, Mary E (2017) CB1 and CB2 Receptor Pharmacology. Adv Pharmacol 80:169-206 |
| Bertini, Simone; Chicca, Andrea; Gado, Francesca et al. (2017) Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor. Bioorg Med Chem 25:6427-6434 |
| Console-Bram, Linda; Ciuciu, Sandra M; Zhao, Pingwei et al. (2017) N-arachidonoyl glycine, another endogenous agonist of GPR55. Biochem Biophys Res Commun 490:1389-1393 |
| Fakhouri, Lara; Cook, Christopher D; Al-Huniti, Mohammed H et al. (2017) Design, synthesis and biological evaluation of GPR55 agonists. Bioorg Med Chem 25:4355-4367 |
| Gherghina, Florin Liviu; Tica, Andrei Adrian; Deliu, Elena et al. (2017) Effects of VPAC1 activation in nucleus ambiguus neurons. Brain Res 1657:297-303 |
| Brailoiu, G Cristina; Deliu, Elena; Barr, Jeffrey L et al. (2017) HIV Tat excites D1 receptor-like expressing neurons from rat nucleus accumbens. Drug Alcohol Depend 178:7-14 |
| Lingerfelt, Mary A; Zhao, Pingwei; Sharir, Haleli P et al. (2017) Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor. Biochemistry 56:473-486 |
| Meza-Aviña, Maria Elena; Lingerfelt, Mary A; Console-Bram, Linda M et al. (2016) Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones. Bioorg Med Chem Lett 26:1827-1830 |
| Gamage, Thomas F; Anderson, Johnathon C; Abood, Mary E (2016) CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling. Cannabis Cannabinoid Res 1:272-280 |
Showing the most recent 10 out of 30 publications
